Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 9/20 | 0.56 |
| ▸ | GRK5 | P34947 | 2/20 | 0.53 |
| ▸ | PAK4 | O96013 | 3/20 | 0.52 |
| ▸ | JAK1 | P23458 | 2/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 3/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 2/20 | 0.48 |
| ▸ | LTK | P29376 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28456343 | 0.76 | TAAR1 (0.66) | PAK4IRAK4MAPTGAALRRK2 | |
| SCHEMBL14547925 | 0.76 | PAK4 (0.57) | PTK2PAK4JAK1IRAK4TTK | |
| SCHEMBL20776757 | 0.73 | PTK2 (1.00) | PTK2GRK5EGFRGAABTK | |
| SCHEMBL14547919 | 0.72 | LRRK2 (0.70) | PTK2GRK5PAK4JAK1IRAK4 | |
| SCHEMBL28452246 | 0.72 | PAK4 (0.51) | PTK2GRK5PAK4JAK1IRAK4 | |
| SCHEMBL28374655 | 0.71 | JAK2 (0.57) | PTK2JAK2 | |
| SCHEMBL15102600 | 0.70 | ADORA3 (0.59) | JAK3EGFRMAPTGAAMEN1 | |
| SCHEMBL14547770 | 0.70 | PTK2 (0.53) | PTK2GRK5PAK4JAK3MAPT | |
| SCHEMBL28612718 | 0.69 | PTK2 (0.81) | PTK2GRK5MEN1KMT2A | |
| SCHEMBL14287378 | 0.69 | LRRK2 (0.69) | PTK2GRK5PAK4JAK3LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | PTK2 781/4885GRK5 1292/4885PAK4 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.